<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="article-commentary" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">105612</article-id><article-id pub-id-type="doi">10.7554/eLife.105612</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Insight</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group><subj-group subj-group-type="sub-display-channel"><subject>Down Syndrome</subject></subj-group></article-categories><title-group><article-title>How a gene fuels ear infections</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Delmaghani</surname><given-names>Sedigheh</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2092-5097</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/><bio><p><bold>Sedigheh Delmaghani</bold> is in the Université Paris Cité, Institut Pasteur, AP-HP, Inserm, CNRS, Fondation Pour l'Audition, Institut de l’Audition, IHU reconnect, Progressive Sensory Disorders, Pathophysiology and Therapy Unit, Paris, France</p></bio></contrib><contrib contrib-type="author" corresp="yes"><name><surname>El-Amraoui</surname><given-names>Aziz</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2692-4984</contrib-id><email>aziz.el-amraoui@pasteur.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/><bio><p><bold>Aziz El-Amraoui</bold> is in the Université Paris Cité, Institut Pasteur, AP-HP, Inserm, CNRS, Fondation Pour l'Audition, Institut de l’Audition, IHU reconnect, Progressive Sensory Disorders, Pathophysiology and Therapy Unit, Paris, France</p></bio></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02feahw73</institution-id><institution>Université Paris Cité, Institut Pasteur, AP-HP, Inserm, CNRS, Fondation Pour l'Audition, Institut de l’Audition, IHU reconnect, Progressive Sensory Disorders, Pathophysiology and Therapy Unit</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>22</day><month>01</month><year>2025</year></pub-date><volume>14</volume><elocation-id>e105612</elocation-id><permissions><copyright-statement>© 2025, Delmaghani and El-Amraoui</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Delmaghani and El-Amraoui</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-105612-v1.pdf"/><related-article related-article-type="commentary-article" ext-link-type="doi" xlink:href="10.7554/eLife.101969" id="ra1"/><abstract><p>The DYRK1A enzyme is a pivotal contributor to frequent and severe episodes of otitis media in Down syndrome, positioning it as a promising target for therapeutic interventions.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>down syndrome</kwd><kwd>otitis media</kwd><kwd>DYRK1A</kwd><kwd>inflammation</kwd><kwd>hearing loss</kwd><kwd>Middle ear</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd><kwd>Human samples</kwd></kwd-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The DYRK1A enzyme is a pivotal contributor to frequent and severe episodes of otitis media in Down syndrome, positioning it as a promising target for therapeutic interventions.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Template</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text><p><bold>Related research article</bold> Tateossian H, Southern A, Vikhe P, Lana-Elola E, Watson-Scales S, Gibbins D, Williams D, Purnell T, Mburu P, Parker A, Norris DP, Santos-Cortez RLP, Herrmann BW, Wells S, Lad HV, Fisher EM, Tybulewicz VL, Brown SD. 2025. DYRK1A kinase triplication is the major cause of otitis media in Down syndrome. <italic>eLife</italic> <bold>14</bold>:RP101969. doi: <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.7554/eLife.101969">10.7554/eLife.101969</ext-link>.</p></boxed-text><p>Otitis media with effusion, or ‘glue ear’, occurs when the middle ear becomes inflamed or infected and fills up with fluid – often due to bacteria or viruses migrating from the nasal passages to the ear through the Eustachian tube (<xref ref-type="bibr" rid="bib8">Nokso-Koivisto et al., 2024</xref>). While this pathology is one of the most common causes of hearing loss worldwide, in most children, episodes of otitis media are temporary and resolve with treatment.</p><p>For individuals with Down syndrome, however, otitis media is both more frequent and more severe, often causing lasting damage to the delicate structures of the ear (<xref ref-type="bibr" rid="bib5">Manickam et al., 2016</xref>; <xref ref-type="bibr" rid="bib6">Maris et al., 2014</xref>). Studies suggest that by age five, nearly 70% of children with Down syndrome will have developed the condition, with many requiring multiple surgical interventions to alleviate it (<xref ref-type="bibr" rid="bib5">Manickam et al., 2016</xref>; <xref ref-type="bibr" rid="bib6">Maris et al., 2014</xref>). The resulting chronic hearing impairment significantly hinders communication and daily functioning, highlighting the need for targeted interventions to improve quality of life. Yet why this condition disproportionately affects those with Down syndrome has remained poorly understood (<xref ref-type="bibr" rid="bib9">Porter et al., 2023</xref>). Now, in eLife, Steve Brown, Hilda Tateossian and colleagues have identified a gene known as <italic>DYRK1A</italic> as a critical driver of otitis media in Down syndrome (<xref ref-type="bibr" rid="bib10">Tateossian et al., 2025</xref>).</p><p>The researchers, who are based at the MRC Harwell Institute, the Francis Crick Institute and other institutes in the UK and US, first used several advanced mouse models which, together, replicate the genetic profile observed in Down syndrome. In humans, the condition is due to the presence of a full or partial extra copy of chromosome 21, often resulting in the overexpression of proteins coded by these multiple triplicated genes. In mice, the sequences equivalent to the genes on human chromosome 21 are spread across a number of mouse chromosomes, including chromosomes 10, 16, 17 (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Examining which type of mice model presented symptoms of otitis media and hearing loss revealed that the condition was associated with the presence of an extra copy of genes on mouse chromosome 16; in particular, further analyses identified a link with a shorter region harboring 12 genes, including one known as <italic>DYRK1A</italic> (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). This sequence, which is present on human chromosome 21, encodes an enzyme involved in various signaling pathways important for development and immunity. Its implication in cognitive disabilities, Alzheimer’s disease and congenital heart defects, for example, has been well-documented (<xref ref-type="bibr" rid="bib7">Murphy et al., 2024</xref>; <xref ref-type="bibr" rid="bib4">Lana-Elola et al., 2024</xref>). Reducing the amount of DYRK1A expressed in the mouse models restored middle ear health, convincingly linking <italic>DYRK1A</italic> to the development of otitis media (<xref ref-type="bibr" rid="bib10">Tateossian et al., 2025</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title><italic>DYRK1A</italic> as a key driver and therapeutic target in Down syndrome-related otitis media.</title><p>(<bold>A</bold>) Mouse models with extra copies of genes on chromosomes 10 (green), 16 (blue), and 17 (pink) mimic the genetic changes seen in human trisomy 21. Experiments conducted on these animals enabled the identification of the Dp(16)1Tyb region (located on mouse chromosome 16, Mmu16) as the genetic driver of Down syndrome-related otitis media. This region carries a gene (bright pink) coding for the DYRK1A protein. (<bold>B</bold>) Further investigations into the Dp1Tyb region (blue) on mouse chromosome 16 allowed Tateossian et al. to refine the locus associated with increased otitis media to a shorter region harboring 12 genes, including <italic>DYRK1A</italic>. Mice in which this region is present in three copies overexpress DYRK1A (blue shape): this enzyme (which includes a kinase and various other domains, including PEST and S/T domains) is an enzyme important for various signaing pathways. DYRK1A overexpression leads to pathological changes that create a middle ear environment prone to persistent infections and effusions. (<bold>C</bold>) DYRK1A inhibitors (blue), including small molecules and natural products, emerge as promising therapeutic agents. Their localized delivery to the middle ear offers a targeted approach to mitigate otitis media; they may also potentially address broader Down syndrome-related health deficits in which <italic>DYRK1A</italic> may be involved, such as deficits in muscle development or cardiac function.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105612-fig1-v1.tif"/><attrib>Image credit: Middle ear illustration adapted from Figure 4 of <xref ref-type="bibr" rid="bib1">Delmaghani and El-Amraoui, 2020</xref> (CC BY 4.0).</attrib></fig><p>Next, Tateossian et al. conducted experiments to uncover how the overexpression of <italic>DYRK1A</italic> was linked to ear health, revealing several interconnected mechanisms. Indeed, elevated levels of DYRK1A were associated with a rise in proinflammatory molecules, known as IL-6 and IL-17, in the fluid present in the middle ear, potentially contributing to sustain chronic inflammation. Mutants also showed upregulated VEGF signaling which, in turn increased the permeability of blood vessels – a process that can result in leakage and therefore exacerbate inflammation and fluid build-up. Finally, electron microscopy approaches revealed that mice overexpressing <italic>DYRK1A</italic> experienced significant loss of the small hairs tasked with clearing fluids and pathogens in the middle ear. Together, these mechanisms create an environment highly susceptible to infections and fluid accumulation.</p><p>To validate these findings in humans, the team analyzed clinical samples from children with Down syndrome. Among the 12 genes studied within the implicated region, <italic>DYRK1A</italic> was the most significantly overexpressed compared to controls, further supporting its role as a central driver of otitis media in Down syndrome. This alignment between animal models and human data highlights the robustness of the study, as well as its potential clinical relevance.</p><p><italic>DYRK1A</italic> is indeed a promising therapeutic target, with the recent development of DYRK1A inhibitors, such as leucettinib-21 and aristolactam BIII, offering many opportunities for targeted interventions (<xref ref-type="bibr" rid="bib3">Kay et al., 2016</xref>; <xref ref-type="bibr" rid="bib7">Murphy et al., 2024</xref>). The accessibility of the middle ear for localized drug delivery makes this a particularly attractive approach (<xref ref-type="fig" rid="fig1">Figure 1C</xref>; <xref ref-type="bibr" rid="bib1">Delmaghani and El-Amraoui, 2020</xref>). Future research should prioritize investigating the safety and efficacy of DYRK1A inhibitors in preclinical and clinical trials. Longitudinal studies in individuals with Down syndrome could also assess whether modulating <italic>DYRK1A</italic> expression confers broader health benefits, such as improvements in cognitive function, cardiac health or immune regulation.</p><p>Despite these breakthroughs, several questions remain unanswered. For instance, how do other genes within the implicated region interact with <italic>DYRK1A</italic> to influence the likelihood of developing otitis media? And to what extent are these genetic effects modulated by environmental factors, such as early-life infections or differences in the communities of microbes present in the ear and respiratory tract (<xref ref-type="bibr" rid="bib2">Elling et al., 2023</xref>)? By starting to shed light on the genetic and biological mechanisms driving otitis media in Down syndrome, the work by Tateossian et al. enables future research studies that hold the potential to transform health outcomes and improve quality of life.</p></body><back><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delmaghani</surname><given-names>S</given-names></name><name><surname>El-Amraoui</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Inner ear gene therapies take off: current promises and future challenges</article-title><source>Journal of Clinical Medicine</source><volume>9</volume><elocation-id>2309</elocation-id><pub-id pub-id-type="doi">10.3390/jcm9072309</pub-id><pub-id pub-id-type="pmid">32708116</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elling</surname><given-names>CL</given-names></name><name><surname>Goff</surname><given-names>SH</given-names></name><name><surname>Hirsch</surname><given-names>SD</given-names></name><name><surname>Tholen</surname><given-names>K</given-names></name><name><surname>Kofonow</surname><given-names>JM</given-names></name><name><surname>Curtis</surname><given-names>D</given-names></name><name><surname>Robertson</surname><given-names>CE</given-names></name><name><surname>Prager</surname><given-names>JD</given-names></name><name><surname>Yoon</surname><given-names>PJ</given-names></name><name><surname>Wine</surname><given-names>TM</given-names></name><name><surname>Chan</surname><given-names>KH</given-names></name><name><surname>Scholes</surname><given-names>MA</given-names></name><name><surname>Friedman</surname><given-names>NR</given-names></name><name><surname>Frank</surname><given-names>DN</given-names></name><name><surname>Herrmann</surname><given-names>BW</given-names></name><name><surname>Santos-Cortez</surname><given-names>RLP</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Otitis media in children with Down syndrome is associated with shifts in the nasopharyngeal and middle ear microbiotas</article-title><source>Genetic Testing and Molecular Biomarkers</source><volume>27</volume><fpage>221</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1089/gtmb.2023.0132</pub-id><pub-id pub-id-type="pmid">37522794</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kay</surname><given-names>LJ</given-names></name><name><surname>Smulders-Srinivasan</surname><given-names>TK</given-names></name><name><surname>Soundararajan</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Understanding the multifaceted role of human Down syndrome kinase DYRK1A</article-title><source>Advances in Protein Chemistry and Structural Biology</source><volume>105</volume><fpage>127</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/bs.apcsb.2016.07.001</pub-id><pub-id pub-id-type="pmid">27567487</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lana-Elola</surname><given-names>E</given-names></name><name><surname>Aoidi</surname><given-names>R</given-names></name><name><surname>Llorian</surname><given-names>M</given-names></name><name><surname>Gibbins</surname><given-names>D</given-names></name><name><surname>Buechsenschuetz</surname><given-names>C</given-names></name><name><surname>Bussi</surname><given-names>C</given-names></name><name><surname>Flynn</surname><given-names>H</given-names></name><name><surname>Gilmore</surname><given-names>T</given-names></name><name><surname>Watson-Scales</surname><given-names>S</given-names></name><name><surname>Haugsten Hansen</surname><given-names>M</given-names></name><name><surname>Hayward</surname><given-names>D</given-names></name><name><surname>Song</surname><given-names>OR</given-names></name><name><surname>Brault</surname><given-names>V</given-names></name><name><surname>Herault</surname><given-names>Y</given-names></name><name><surname>Deau</surname><given-names>E</given-names></name><name><surname>Meijer</surname><given-names>L</given-names></name><name><surname>Snijders</surname><given-names>AP</given-names></name><name><surname>Gutierrez</surname><given-names>MG</given-names></name><name><surname>Fisher</surname><given-names>EMC</given-names></name><name><surname>Tybulewicz</surname><given-names>VLJ</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Increased dosage of DYRK1A leads to congenital heart defects in a mouse model of Down syndrome</article-title><source>Science Translational Medicine</source><volume>16</volume><elocation-id>eadd6883</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.add6883</pub-id><pub-id pub-id-type="pmid">38266108</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manickam</surname><given-names>V</given-names></name><name><surname>Shott</surname><given-names>GS</given-names></name><name><surname>Heithaus</surname><given-names>D</given-names></name><name><surname>Shott</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Hearing loss in Down syndrome revisited - 15 years later</article-title><source>International Journal of Pediatric Otorhinolaryngology</source><volume>88</volume><fpage>203</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/j.ijporl.2016.07.012</pub-id><pub-id pub-id-type="pmid">27497415</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maris</surname><given-names>M</given-names></name><name><surname>Wojciechowski</surname><given-names>M</given-names></name><name><surname>Van de Heyning</surname><given-names>P</given-names></name><name><surname>Boudewyns</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A cross-sectional analysis of otitis media with effusion in children with Down syndrome</article-title><source>European Journal of Pediatrics</source><volume>173</volume><fpage>1319</fpage><lpage>1325</lpage><pub-id pub-id-type="doi">10.1007/s00431-014-2323-5</pub-id><pub-id pub-id-type="pmid">24816633</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>AJ</given-names></name><name><surname>Wilton</surname><given-names>SD</given-names></name><name><surname>Aung-Htut</surname><given-names>MT</given-names></name><name><surname>McIntosh</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Down syndrome and DYRK1A overexpression: relationships and future therapeutic directions</article-title><source>Frontiers in Molecular Neuroscience</source><volume>17</volume><elocation-id>1391564</elocation-id><pub-id pub-id-type="doi">10.3389/fnmol.2024.1391564</pub-id><pub-id pub-id-type="pmid">39114642</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nokso-Koivisto</surname><given-names>J</given-names></name><name><surname>Ehrlich</surname><given-names>GD</given-names></name><name><surname>Enoksson</surname><given-names>F</given-names></name><name><surname>Komatsu</surname><given-names>K</given-names></name><name><surname>Mason</surname><given-names>K</given-names></name><name><surname>Melhus</surname><given-names>Å</given-names></name><name><surname>Patel</surname><given-names>JA</given-names></name><name><surname>Vijayasekaran</surname><given-names>S</given-names></name><name><surname>Ryan</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Otitis media: interactions between host and environment, immune and inflammatory responses</article-title><source>International Journal of Pediatric Otorhinolaryngology</source><volume>176</volume><elocation-id>111798</elocation-id><pub-id pub-id-type="doi">10.1016/j.ijporl.2023.111798</pub-id><pub-id pub-id-type="pmid">38041988</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>HL</given-names></name><name><surname>Braza</surname><given-names>MD</given-names></name><name><surname>Knox</surname><given-names>R</given-names></name><name><surname>Vicente</surname><given-names>M</given-names></name><name><surname>Buss</surname><given-names>E</given-names></name><name><surname>Leibold</surname><given-names>LJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>“I think it impacts all areas of his life”: perspectives on hearing from mothers of individuals with Down syndrome</article-title><source>Journal of Applied Research in Intellectual Disabilities</source><volume>36</volume><fpage>333</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1111/jar.13062</pub-id><pub-id pub-id-type="pmid">36527178</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tateossian</surname><given-names>H</given-names></name><name><surname>Southern</surname><given-names>A</given-names></name><name><surname>Vikhe</surname><given-names>P</given-names></name><name><surname>Lana-Elola</surname><given-names>E</given-names></name><name><surname>Watson-Scales</surname><given-names>S</given-names></name><name><surname>Gibbins</surname><given-names>D</given-names></name><name><surname>Williams</surname><given-names>D</given-names></name><name><surname>Purnell</surname><given-names>T</given-names></name><name><surname>Mburu</surname><given-names>P</given-names></name><name><surname>Parker</surname><given-names>A</given-names></name><name><surname>Norris</surname><given-names>DP</given-names></name><name><surname>Santos-Cortez</surname><given-names>RLP</given-names></name><name><surname>Herrmann</surname><given-names>BW</given-names></name><name><surname>Wells</surname><given-names>S</given-names></name><name><surname>Lad</surname><given-names>HV</given-names></name><name><surname>Fisher</surname><given-names>EM</given-names></name><name><surname>Tybulewicz</surname><given-names>VL</given-names></name><name><surname>Brown</surname><given-names>SD</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>DYRK1A kinase triplication is the major cause of otitis media in Down syndrome</article-title><source>eLife</source><volume>14</volume><elocation-id>RP101969</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.101969.1</pub-id></element-citation></ref></ref-list></back></article>